Peptide Vaccine for Fibrolamellar Cancer and Related Tumors
Part of Cancer clinical trials.
This trial tests a vaccine designed to target cancer cells with a specific genetic change (DNAJB1-PRKACA). It is for people whose fibrolamellar liver cancer or other tumors with this change are in complete remission after prior treatment, to help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a tumor with the DNAJB1-PRKACA fusion gene.
- You must have no signs of cancer left after previous treatments (complete remission).
- You must be at least 12 years old (if under 18, enrollment starts after 6 adults have joined).
- You should be able to do daily activities with little to no help (ECOG score 0-2).
- You cannot be pregnant or breastfeeding, and must use effective birth control during and for 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a personalized peptide vaccine (targeting the DNAJB1-PRKACA fusion) combined with immunotherapy drugs to treat fibrolamellar hepatocellular carcinoma (FLC) or other eligible non-FLC cancers with the same gene fusion. It aims to see whether this immune-based treatment can shrink tumors and improve outcomes safely.
This Phase 1 study tests a custom vaccine made to match a specific cancer genetic change (DNAJB1-PRKACA fusion). It’s combined with an approved immunotherapy (immune checkpoint inhibitor) to help your immune system recognize and fight the cancer. You may be considered if your cancer is advanced or has spread and you meet several blood/organ and health requirements.
This trial tests a vaccine targeting a specific fusion protein found in fibrolamellar carcinoma, combined with two immunotherapy drugs and a glutamine blocker. It is for patients whose cancer has gotten worse despite previous treatment.
This trial tests a new combination of two drugs—DRP-104 and durvalumab—to see if they can shrink or slow advanced fibrolamellar carcinoma, a rare liver cancer. It is for patients whose cancer has gotten worse even after immunotherapy treatment.
This trial tests a personalized mRNA vaccine made from your tumor's unique genetic markers. It is for people with advanced liver cancer who have not yet received any treatment.
This trial tests a new mRNA vaccine for people with advanced liver cancer that has returned or spread after other treatments. The vaccine aims to help your immune system fight the cancer more effectively.
Hear when a new Fibrolamellar Hepatocellular Carcinoma (FLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.